Obesity Clinical Trial
— NUTRIBIOTAOfficial title:
Personalized Modulation of the Microbiota Through the Intelligent Design of Foods and Ingredients Based on Enterotype-Based Diagnosis (NUTRIBIOTA). Nutritional Intervention in Humans
Verified date | February 2023 |
Source | Clinica Universidad de Navarra, Universidad de Navarra |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intestinal flora or microbiota is the group of bacteria that live in the intestine, in a symbiotic relationship with the human body. It is estimated that human beings have around 2,000 different bacteria species. The gut microbiota plays a key in many of the body's functions. Hence, the analysis of the gut microbiome provides insight into the state of the microbiota as an indicator of overall health due to its metabolic, protective and nutritional functions. A balanced diet promotes the formation and maintenance of a well-structured microbiota, in which the different species of microorganisms cohabit in a balanced and controlled system. The study is based on the hypothesis that the intake of certain plant-based foods rich in various active ingredients (especially non-digestible carbohydrates, certain types of fats and polyphenols) can modulate the microbiota and thus improve the health status of the human population. Taking into account this background, the objective of this study is to assess the effect of the inclusion of functional foods and ingredients within a balanced diet on the composition of the microbiota and also on health parameters associated with metabolic disease.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 15, 2021 |
Est. primary completion date | March 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - Volunteers of both sexes with ages between 20 and 65 years. - Volunteers with a body mass index between 24.9 and 34.9 kg / m2. - Volunteers with intestinal dysbiosis. - Physical examination and normal vital signs or clinically irrelevant for the study. - Subjects must be able to understand and be willing to sign the informed consent. Exclusion Criteria: - Volunteers who have taken antibiotics or corticosteroids one month before the start of the intervention or antihistamines 15 days before the start of the intervention. - Volunteers who are taken gastric protectors chronically. - Volunteers who present changes in their pharmacological treatment in the last 3 months before the start of the study. - Volunteers with intestinal pathologies (ulcerative colitis, Crohn's disease, or similar). - Volunteers suffering from Covid-19 |
Country | Name | City | State |
---|---|---|---|
Spain | Center for Nutrition Research. University of Navarra | Pamplona | Navarra |
Lead Sponsor | Collaborator |
---|---|
Clinica Universidad de Navarra, Universidad de Navarra |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of fecal microbiota composition | Measured by analyzing the variable regions V3-V4 of the prokaryotic 16S rRNA (ribosomal ribonucleic acid) gene sequences, which gives 460 bp amplicons in a two-round PCR protocol. The kit used will be the Nextera® XT DNA Index Kit, FC-131-1002 (Illumina, San Diego, CA, USA).
In the first step, PCR is used to amplify a template out of a DNA fecal sample using specific primers from Illumina. Then, sequencing libraries are built with the MiSeq® Reagent Kit v3 (600 cycles) MS-102-3003 (Illumina). Finally, paired-end sequencing is performed on a MiSeq platform (Illumina) with a 600 cycles Miseq run. Fecal samples are self-collected by the volunteers' fecal samples using OMNIgene.GUT kits from DNA Genotek (Ottawa, ONT, Canada), according to the standard instructions provided by the company |
The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of glucose concentration | Glucose concentration will be reported in mg/dl | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of total cholesterol concentration | Total cholesterol concentration will be reported in mg/dl | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of LDL-cholesterol concentration | LDL-cholesterol concentration will be reported in mg/dl by Friedewald equation. | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of HDL-cholesterol concentration | HDL-cholesterol concentration will be reported in mg/dl | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of triglyceride concentration | Triglyceride concentration will be reported in mg/dl | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of aspartate aminotransaminase concentration | Aspartate aminotransaminase concentration will be reported in mg/dl | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of alanine aminotransferase concentration | Alanine aminotransferase concentration will be reported in U/L | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of insulin concentration | Insulin concentration will be reported in U/L | Clinical The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).day 1 and 3 | |
Secondary | Change of body weight | Body weight will be reported in kg | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of body mass index | Body weight will be reported in kg | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of body fat mass percentage | Body fat mass will be reported in percentage | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of body lean mass | Body lean mass will be reported in kg | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of body water percentage | Body water will be reported in percentage | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of visceral fat level | Visceral fat level will be reported | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of physical activity | Physical activity level will be monitored by physical activity questionnaire | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). | |
Secondary | Change of dietary intake | Dietary energy and macronutrient intake will be monitored by a food frequency questionnaire | The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |